We have accumulated a sizeable portfolio of patents and patent applications in the course of our research, which we believe constitutes a very valuable business asset. The major patents relate primarily to our therapeutic product candidates as well as our technologies and other discoveries for which no product candidate has yet been identified. Currently, our portfolio included 179 active U.S. patents and more than 400 issued foreign patents, with a number of U.S. and foreign patent applications pending.